Sam Brusco, Associate Editor09.07.22
Abbott began the European launch of its Amplatzer Talisman PFO occlusion system, which treats people with a patent foramen ovale (PFO)—a hole in the heart that doesn’t close at birth—who’ve had a stroke and are at risk of having another.
Talisman PFO occluders are pre-attached to the delivery cable to reduce doctors’ preparation time and boost ease-of-use.
For those who’ve suffered a stroke, occlusion (closure) of the PFO using a minimally invasive, catheter-based procedure using a device like Talisman to seal off the opening can reduce the risk of another stroke.
"Guidelines from industry organizations and clinical trial data continue to reinforce the benefits of PFO closure for people who have had a PFO-associated stroke," Matthew Daniels, BSc, MA, MB BChir, MRCP, FSCAI, honorary consultant cardiologist in Manchester, England, who completed the first European procedure with the Talisman system, told the press. "We're excited that physicians around Europe now have access to the Talisman device to help reduce patients' risk and worry of experiencing another stroke."
The Talisman system accommodates a range of patient anatomies and an updated 30mm occluder size optimizes how it fits in the heart. Talisman is fully recapturable and repositionable to make easy adjustments for accurate placement.
"Our trusted PFO closure technology has been used to treat more than 180,000 people worldwide and we haven't let up on continuing to innovate to best serve physicians and patients," said Michael Dale, senior VP of Abbott's structural heart business. "The Talisman system simplifies the procedure for doctors and helps patients quickly get back to living fuller, healthier lives."
Talisman earned U.S. Food and Drug Administration (FDA) approval for PFO closure in September 2021.
Talisman PFO occluders are pre-attached to the delivery cable to reduce doctors’ preparation time and boost ease-of-use.
For those who’ve suffered a stroke, occlusion (closure) of the PFO using a minimally invasive, catheter-based procedure using a device like Talisman to seal off the opening can reduce the risk of another stroke.
"Guidelines from industry organizations and clinical trial data continue to reinforce the benefits of PFO closure for people who have had a PFO-associated stroke," Matthew Daniels, BSc, MA, MB BChir, MRCP, FSCAI, honorary consultant cardiologist in Manchester, England, who completed the first European procedure with the Talisman system, told the press. "We're excited that physicians around Europe now have access to the Talisman device to help reduce patients' risk and worry of experiencing another stroke."
The Talisman system accommodates a range of patient anatomies and an updated 30mm occluder size optimizes how it fits in the heart. Talisman is fully recapturable and repositionable to make easy adjustments for accurate placement.
"Our trusted PFO closure technology has been used to treat more than 180,000 people worldwide and we haven't let up on continuing to innovate to best serve physicians and patients," said Michael Dale, senior VP of Abbott's structural heart business. "The Talisman system simplifies the procedure for doctors and helps patients quickly get back to living fuller, healthier lives."
Talisman earned U.S. Food and Drug Administration (FDA) approval for PFO closure in September 2021.